Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03965429

Acronym

SIA-CSH

Enrollment

1020

Registered

2019-05-29

Start date

2019-05-14

Completion date

2029-05-31

Last updated

2025-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Hemopathy

Keywords

malignant hemopathy, allogeneic hematopoietic stem cell transplant, blood collection

Brief summary

Description of the evolution of the biological characteristics of immune blood populations and biomarkers of interest in patients who have received allogeneic hematopoietic stem cell transplantation.

Detailed description

a more in-depth analysis of the different immune cell sub-populations as well as serum markers (cytokines) would provide a better understanding of post-allograft immune reconstitution mechanisms and identify potential immunologic biomarkers predictive of GVH or relapse.

Interventions

OTHERBlood samples (additional tubes from care) longitudinal

Some sampling times will be systematic, while others will only be performed in the presence of specific post-transplant clinical events (eg relapse, GVH ...).

OTHERBlood samples (additional tubes from care) at inclusion

In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor. A single blood sample of 28 mL (7 EDTA tubes) will be made. In order not to represent an additional sample for the donor, this sample will be taken before the mobilization of the hematopoietic stem cells, during the biological assessment required for the biological donation qualification.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Allogeneic hematopoietic stem cell transplant for hematological malignancy 2. Patients 18 years of age or older 3. Signed consent to participation 4. Membership in a social security scheme, or beneficiary of such a scheme.

Exclusion criteria

* A person of legal age subject to a legal protection measure (major under guardianship, curatorship or court bail), or unable to express consent (language criteria included).

Design outcomes

Primary

Measure	Time frame	Description
Evolution of the immune blood populations in patients who have received allogeneic hematopoietic stem cell transplantation.	5 years after HSC transplantation	longitudinal study of the immune subpopulations of allografted patients for hematological malignancies.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026